<DOC>
	<DOCNO>NCT00743912</DOCNO>
	<brief_summary>The primary objective study determine rifaximin , administer daily effect cytochrome P450 ( CYP ) isoenzyme 3A4 , examine change pharmacokinetics midazolam ( CYP3A4 substrate ) , co-administered .</brief_summary>
	<brief_title>Open-Label Study Evaluate Effect Rifaximin Midazolam Normal Healthy Volunteers</brief_title>
	<detailed_description>This single-site , single-arm , open-label , drug-interaction study examines effect rifaximin ( RFX ) , 550 mg 3 time daily ( TID ; 1650 mg/day ) , orally administer ( PO ) midazolam ( MDZ ) 2 mg ( administer 2 mg dose 1 mL midazolam HCL Syrup ; 2 mg/mL ) dose 7 14 consecutive day , respectively .</detailed_description>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Patient medically normal Patient normal laboratory value Patient ability understand requirement study HIV Hepatitis B Hepatitis C History renal , hepatic , endocrine , oncological , gastrointestinal cardiovascular disease . History epilepsy , asthma , diabetes , psychosis , glaucoma severe head injury .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>rifaximin</keyword>
	<keyword>midazolam</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>